Stay Informed With Our Latest Updates

Webcasts July 30, 2026

Webcast: Most Favored Nation Drug Pricing Reforms: Implications for Dealmaking

Join our lawyers for a recorded webcast examining the rapidly revolving Most Favored Nation (“MFN”) and drug pricing landscape and …

Accolades June 8, 2026

Gibson Dunn Recognized in 2026 IAM Patent 1000 Guide of World’s Leading Patent Professionals

Gibson Dunn is recognized in the 2026 edition of the IAM Patent 1000 guide, which identifies “world-class patent expertise across both individual practitioners and private practice firms.”

Client Alert March 11, 2026

Royalty Finance in Life Sciences – Market Update 2026

This Royalty Finance Market Update provides an analysis of publicly reported royalty finance transactions for 2020 through 2025 in the life sciences sector, focusing on both traditional and synthetic royalty transactions.

Firm News February 25, 2026

Gibson Dunn Advises BVF Partners L.P. on up to $400 Million Financing for Immunic, Inc.

Gibson Dunn represented BVF Partners L.P. as lead investor in the up to $400 million private placement financing for Immunic, Inc., a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases.

Firm News February 4, 2026

Advised BioCryst Pharmaceuticals on $400 Million Debt Financing for Acquisition of Astria Therapeutics

Gibson Dunn represented BioCryst Pharmaceuticals, Inc. in connection with a $400 million senior secured term loan facility to finance the acquisition of Astria Therapeutics, Inc. 

Firm News January 23, 2026

Gibson Dunn Advises BioCryst Pharmaceuticals on $400 Million Debt Financing for Acquisition of Astria Therapeutics

Gibson Dunn represented BioCryst Pharmaceuticals, Inc. in connection with a $400 million senior secured term loan facility, to finance, in part, the acquisition of Astria Therapeutics, Inc.

Client Alert January 12, 2026

Life Sciences 2026 Outlook

The life sciences industry enters 2026 with a constructive set of tailwinds, following a second half of 2025 in which dealmaking activity showed clearer signs of normalization after a prolonged slowdown. While risks remain, particularly around geopolitics, trade policy, and regulatory priorities, the overall setup for 2026 is cautiously constructive, with improved visibility into execution pathways for well-positioned assets and platforms.

Royalty Finance Tracker

The Gibson Dunn team has represented clients in royalty finance transactions with a total aggregate value of approximately $8 Billion.